The US Food and Drug Administration has approved the use of the injectable drug tocilizumab for the treatment of giant cell arteritis, making it the first approved drug for this condition. Giant cell arteritis is an inflammatory disease belonging to a group of conditions referred to as vasculitis. It affects medium and large blood vessels, mainly supplying to the head and neck region, thereby affecting blood flow through them.